Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Cancer Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://www.ncbi.nlm.nih.gov/pubmed/24347491
http://dx.doi.org/10.1002/ijc.28669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://www.ncbi.nlm.nih.gov/pubmed/24347491
http://dx.doi.org/10.1002/ijc.28669

Ejemplares similares